



## OPEN ACCESS

APPROVED BY  
Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

\*CORRESPONDENCE  
Frontiers Production Office  
✉ production.office@frontiersin.org

RECEIVED 22 August 2023  
ACCEPTED 22 August 2023  
PUBLISHED 27 September 2023

CITATION  
Frontiers Production Office (2023) Erratum:  
Preoperative immunological plasma  
markers TRAIL, CSF1, and TIE2 predict  
survival after resection for biliary tract  
cancer.  
*Front. Oncol.* 13:1281693.  
doi: 10.3389/fonc.2023.1281693

COPYRIGHT  
© 2023 Frontiers Production Office. This is  
an open-access article distributed under the  
terms of the [Creative Commons Attribution  
License \(CC BY\)](#). The use, distribution or  
reproduction in other forums is permitted,  
provided the original author(s) and the  
copyright owner(s) are credited and that  
the original publication in this journal is  
cited, in accordance with accepted  
academic practice. No use, distribution or  
reproduction is permitted which does not  
comply with these terms.

# Erratum: Preoperative immunological plasma markers TRAIL, CSF1, and TIE2 predict survival after resection for biliary tract cancer

Frontiers Production Office\*

Frontiers Media SA, Lausanne, Switzerland

## KEYWORDS

cholangiocarcinoma (CCA), gallbladder cancer (GBC), prognostic biomarkers, tumor associated macrophage (TAM), biliary tract cancer (BTC)

## An Erratum on

### Preoperative immunological plasma markers TRAIL, CSF1, and TIE2 predict survival after resection for biliary tract cancer

by Jansson H, Cornillet M, Sun D, Filipovic I, Stureson C, O'Rourke CJ, Andersen JB, Björkström NK and Sparrelid E (2023) *Front. Oncol.* 13:1169537. doi: 10.3389/fonc.2023.1169537

Due to a production error, there was a mistake in the legend for [Figure 1](#) as published. The term “pCCA” was incorrectly formatted as “PCCA”. The correct legend appears below. The publisher apologizes for this mistake.

The original version of this article has been updated.




FIGURE 1

Study flow chart for the inclusion of patients with BTC. BTC, biliary tract cancer; GBC, gallbladder cancer; iCCA, intrahepatic cholangiocarcinoma; pCCA, perihilar cholangiocarcinoma.